60.75
Report ID:
SQMIG35I2222 |
Region:
Global |
Published Date: August, 2024
Pages:
157
|Tables:
64
|Figures:
75
Global Ophthalmic Drugs Market size was valued at USD 30.90 Billion in 2022 and is poised to grow from USD 33.31 Billion in 2023 to USD 60.75 Billion by 2031, at a CAGR of 7.8% during the forecast period (2024- 2031).
Increasing research and development efforts aimed at creating innovative ophthalmic drugs, coupled with strategic initiatives by key industry players, are expected to drive demand in the ophthalmic drugs market. Additionally, unmet medical needs in the field of ophthalmology are likely to contribute to market growth. According to a World Health Organization report from October 2021, approximately 2.2 billion people suffer from distance or near vision impairment disorders, with at least 1 billion of these cases being preventable through appropriate treatment. The primary cause of blindness and vision impairment is age-related, and this high prevalence places a significant financial burden on governments. For example, vision impairment resulting from myopia alone is estimated to cost USD 244 billion. Consequently, the prevalence of eye-related diseases is expected to create growth opportunities in the ophthalmic drugs market.
The COVID-19 pandemic hurt the ophthalmic drugs market. According to the Clinical Ophthalmology Journal in November 2021, an analysis of pre-pandemic and post-pandemic data revealed significant declines in visual field checkups (93.84%), clinical visits (92.52%), medication releases (19.63%), and surgical procedures (72.74%). This decline indicates a reduced treatment of glaucoma and other ophthalmic disorders. However, with the widespread availability of COVID-19 vaccines and decreasing COVID-19 cases, the market is expected to rebound.
The increase in research and development activities and investments by leading companies is projected to drive ophthalmic drugs market growth in the coming years. For example, Alcon, a leader in eye care, increased its R&D spending from USD 673 million in 2020 to USD 842 million in 2021. Alcon offers a wide range of products, including contact lenses, cataract treatments, and glaucoma products. Additionally, the presence of a robust pipeline of promising drug candidates is expected to support market growth. For instance, Nicox, a novel eye therapeutics company, is conducting phase III trials for its investigational candidate NCX 470, a novel NO-donating PG analog expected to be on the market by 2029.
Furthermore, strategic initiatives undertaken by leading companies are likely to accelerate the growth of the ophthalmic drugs market. For example, in June 2022, Novartis Pharmaceuticals Corporation announced its acquisition of Kedalion Therapeutics for its innovative AcuStream technology, strengthening its ophthalmic product portfolio. Similarly, in June 2022, Amring Pharmaceuticals Inc. received FDA approval for its preservative-free generic Timolol Maleate Ophthalmic Solution, indicated for the treatment of open-angle glaucoma and ocular hypertension.
Global Market Size
60.75
Largest Segment
Prescription Drugs
Fastest Growth
Prescription Drugs
Growth Rate
ProductPrescription Drugs, and OTC DrugDosage Form CAGR
To get more reports on the above market click here to Buy The Report
The global ophthalmic drugs market is segmented based on drug class, drug disease, drug dosage, drug route of administration, dosage type, product type and region. Based on product, the market is segmented into prescription durgs, OTC drugs. Based on drug class, the market is segmented into Anti-allergy, Anti-inflammatory (Non-steroidal drugs, Steroidal drugs), Anti-VEGF Agents, Anti-glaucoma, Gene and Cell Therapy, Others. Based on disease, the market is segmented into Dry Eye (Gels, Eye Solutions & Suspensions, Capsules & Tablets, Eye Drops, Ointments), Allergies (Gels, Eye Solutions & Suspensions, Capsules & Tablets, Eye Drops, Ointments), Glaucoma (Gels, Eye Solutions & Suspensions, Capsules & Tablets, Eye Drops, Ointments), Infection (Gels, Eye Solutions & Suspensions, Capsules & Tablets, Eye Drops, Ointments), Retinal disorders (Type {Macular Degeneration, Diabetic Retinopathy}, Dosage Type {Gels, Eye Solutions & Suspensions, Capsules & Tablets, Eye Drops, Ointments}), Uveitis (Gels, Eye Solutions & Suspensions, Capsules & Tablets, Eye Drops, Ointments), Others. Based on dosage form, the market is segmented into gels, eye solutions and suspensions, capsules and tablets, eye drops, ointments, others. Based on drug route of administration market is segmented into, topical local ocular systemic. Based on type, the market is segmented into branded drugs, generic drugs. Based on Region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.
Ophthalmic Drugs Market Analysis by Product
Prescription drugs segment accounted for 58.8% of all revenue in 2022, and it is anticipated that this sector would continue to dominate the market for the entire forecast period. This segment's growth can be attributed to the increasing prevalence of ophthalmic disorders such as age-related macular degeneration (AMD) and diabetic retinopathy. Prescription drugs offer improved efficacy and better safety, which are key factors driving the demand for this segment. Some notable prescription drugs in the market include Lotemax gel/ointment, Zylet, Durezol, Bepreve (bepotastine besilate ophthalmic solution), and prescription artificial tears. Bepreve, for example, is an antihistamine used to treat allergic conjunctivitis.
The OTC drugs segment is expected to grow steadily at a rate of 8.5%. This growth can be attributed to factors such as easy patient access, the rise of e-pharmacies, and an increase in product launches of OTC eye drops. For instance, in April 2022, Théa Pharma Inc announced the commercial availability of the iVIZIA line of OTC eye care products in the U.S. These products are available in various dosage forms, including gels, emulsions, capsules, ointments, and eye drops.
Ophthalmic Drugs Market Analysis by Dosage Form
In 2022, The eye drops segment held the largest revenue share of 39.3%. This segment's growth is driven by factors such as the increasing availability of over-the-counter (OTC) eye drops, patient compliance considerations, and a high incidence of eye disorders. Additionally, the introduction of novel eye drop formulations is expected to further fuel the demand for this segment. For example, in January 2022, Alcon launched its systane complete preservative-free eye drops, offering a new option for consumers.
Ophthalmic gels are applied directly to the eyelids or the periphery of the eye. These gels, which are viscous liquids, are used to treat conditions such as uveitis, chronic inflammation, and cataracts. Aqueous gel formulations that utilize hydrophilic polymers and stimuli-responsive polymers are particularly attractive for investment in this market. Gels allow for the incorporation of pharmaceutical drugs to achieve the desired therapeutic effect and bioactivity at specific ocular sites. The increasing entry of OTC products in the ophthalmic gels segment has led to intense competitive rivalry among market players.
Ophthalmic Drugs Market Analysis by Region
North America is the largest market for ophthalmology drugs and devices, followed by Europe and Asia. North America and Europe is expected to grow at a slower pace, primarily due to the economic slowdown and saturation in these markets. APAC is an unsaturated market, especially China and India, and these regions are expected to drive the growth of the overall ophthalmology market, mainly due to growing awareness of eye diseases and increasing disposable income.
To get detailed analysis on other segments, Request For Free Sample Report
In 2022, North America emerged as the leading region in the ophthalmic drugs market share, capturing the largest revenue share of 39.3%. The growth of this region can be attributed to several factors, including a higher prevalence of eye diseases and increasing awareness about these conditions. The region has witnessed significant research and development activities by key market players, which have contributed to its growth. Additionally, the presence of leading companies like Alcon, Pfizer Inc, and Bausch and Lomb has further bolstered the market in North America. For instance, in June 2022, Harrow Health Inc announced the commercial availability of MAXITROL and IOPIDINE 1% in the United States.
The fastest growth is anticipated to occur in Asia Pacific, where a projected 9.6% CAGR is expected. The large patient pool, high disease prevalence, and rise of regional businesses are all responsible for this expansion. Although the Asia Pacific region has the highest patient base for eye diseases, the treatment rate remains relatively low. However, various strategic initiatives undertaken by market players are expected to drive growth in this region.
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
Ophthalmic Drugs Market Drivers
Increasing Prevalence of Eye Disorders
Technological Advancements and Innovations
Ophthalmic Drugs Market Restraints
Stringent Regulatory Approval Processes
High Cost of Treatment
Request Free Customization of this report to help us to meet your business objectives.
The global ophthalmic drugs market is characterized by the presence of several key players, each striving to gain a significant market share. These companies focus on strategies such as new product launches, partnerships, mergers and acquisitions, and research and development activities to stay competitive and meet the evolving needs of patients and healthcare professionals. The competitive landscape also includes other major players such as Bayer AG, Johnson & Johnson, Merck & Co., Inc., and Bausch Health Companies Inc., among others. These companies continuously invest in research and development activities to introduce new and improved ophthalmic drugs, strengthen their market presence, and address unmet medical needs. In addition to established pharmaceutical companies, the market also witnesses the presence of smaller and emerging companies that focus on niche segments and innovative approaches. This dynamic competitive landscape fosters innovation, enhances treatment options, and benefits patients in the global ophthalmic drugs market.
Top Player’s Company Profiles in Ophthalmic Drugs Market
Ophthalmic Drugs Market Recent Developments
Increasing Emphasis on Personalized Medicine:
Growing Adoption of Digital Health Technologies:
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Correlates, and Analyzes the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our global ophthalmic drugs market analysis, the market is driven by several factors. The increasing prevalence of eye diseases and disorders worldwide is a major driver. As the global population continues to age and the incidence of chronic diseases rises, the demand for effective ophthalmic drugs increases. The market also faces certain challenges and restraints. One of the key challenges is the high cost of ophthalmic drugs, which can limit their accessibility, particularly in developing regions. Moreover, stringent regulatory requirements and the lengthy approval process for new drugs pose challenges to market players. The global ophthalmic drugs market is driven by the increasing prevalence of eye disorders, advancements in drug formulations, and growing awareness about eye health. While there are challenges and restraints, the market offers opportunities for innovation and growth. The development of cost-effective drugs, expansion into untapped markets, and strategic collaborations can further propel the market in the coming years.
Report Metric | Details |
---|---|
Market size value in 2022 | USD 30.90 Billion |
Market size value in 2031 | USD 60.75 Billion |
Growth Rate | 7.8% |
Base year | 2023 |
Forecast period | 2024- 2031 |
Forecast Unit (Value) | USD Billion |
Segments covered |
|
Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
Companies covered |
|
Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Executive Summary
Market overview
Parent Market Analysis
Market overview
Market size
KEY MARKET INSIGHTS
COVID IMPACT
MARKET DYNAMICS & OUTLOOK
Market Size by Region
KEY COMPANY PROFILES
For the Ophthalmic Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Ophthalmic Drugs Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Ophthalmic Drugs Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the Ophthalmic Drugs Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.
Report ID: SQMIG35I2222
sales@skyquestt.com
USA +1 351-333-4748